Specialty
Cataract & Refractive Dermatology General Ophthalmology Glaucoma Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Retina’s Believe It or Not: Case Challenges 2018

By: David Brown, MD; Peter Kaiser, MD; Dante J. Pieramici, MD; John D. Pitcher, III, MD; Sunil Srivastava, MD; Nathan C. Steinle, MD

Webinar Credits: 1.5

Expiration Date: Wednesday, July 31, 2019
Release Date: July 2018

Learning Objectives

Upon completion of this activity, the participant should be able to:

Discuss a wide variety of treatment approaches for numerous vitreoretinal disease states.
Compare the most recent monotherapy and combination therapy clinical study evidence using available therapies for AMD, DME, and RVO.
Develop individualized treatment plans for patients with retina disorders that use a combination of imaging, treat and extend, or treat and observe.
Apply case study examples to real world clinical settings.

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

David Brown, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Inc.; Adverum Biotechnologies; Bayer; Carl Zeiss Meditec; Clearside Biomedical; Genentech, Inc.; Heidelberg Pharma; Novartis; Optos; Regeneron Pharmaceuticals; Samsung; and Santen Pharmaceutical Company;. Grant Research: Alcon; Allergan, Inc.; Clearside Biomedical; Genentech, Inc.; Novartis; and Regeneron Pharmaceuticals.

Peter Kaiser, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Aerpio Therapeutics; Alcon; Allergan Inc.; Allegro Ophthalmics; Bayer Corporation; Biogen, Inc.; Novartis, Ohr Pharmaceutical, Inc.; Ophthotech Corporation; Regeneron Pharmaceuticals, Inc.; Santen Pharmaceutical Company; Shire Plc.; and ThromboGenics NV. Stockholder: Ohr Pharmaceutical, Inc.

Dante J. Pieramici, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro; Genentech, Inc.; Kodiac; Novartis; Regeneron Pharmaceuticals. Grant/Research Support: Aerpio Therapeutics; Allegro Ophthalmics; Genentech, Inc.; Novartis; Ophthea; Regeneron Pharmaceuticals; Regenxbio; and RPE Patch.

John D. Pitcher, III, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Inc.; Genentech, Inc. and Regeneron Pharmaceuticals, Inc. Speakers Bureau; Genentech.

Sunil Srivasta, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Santen Pharmaceutical Co, Ltd. Grant/Research Support: Allergan, Inc.

Nathan C. Steinle, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences; Genentech; Notal Vision; and Vortex Surgery. Advisory Board/Speaker’s Bureau: Genentech; and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Carl Zeiss Meditec;  Genentech; and Regeneron Pharmaceuticals, Inc.

Editorial Support Disclosure
Michelle Dalton, Writer, Susan Gallagher-Pecha, director of client services and project management, Evolve Medical Education LLC, and Erin Fletcher, MIT, Evolve Medical Education LLC, have no real or apparent conflicts of interest to report. Jaya Kumar, MD, peer reviewer has no conflict of interest to report.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, Regeneron Pharmaceuticals, Inc. or Carl Zeiss Meditec, Inc.

Pretest

Video Resources

Part one

Part two

Part three

Part four

Part five

Part six

Part seven

Next

Test

Instructions

Step 1 of 2

50%
  • AgreeNeutralDisagree
    Discuss a wide variety of treatment approaches for numerous vitreoretinal disease states
    Compare the most recent monotherapy and combination therapy clinical study evidence using available therapies for AMD, DME, and RVO
    Develop individualized treatment plans for patients with retina disorders that use a combination of imaging, treat and extend, or treat and observe
    Apply case study examples to real world clinical settings
Back